Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 7/20 | 0.55 |
| ▸ | TUBB | P07437 | 7/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 7/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 7/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 7/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 7/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 7/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albendazole Oxide SCHEMBL29564405 | 1.00 | LMNA (0.55) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL3175532 | 0.99 | LMNA (0.54) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL11662850 | 0.91 | LMNA (0.53) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL30580728 | 0.91 | LMNA (0.64) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL17968582 | 0.91 | LMNA (0.64) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL1649240 | 0.91 | LMNA (0.64) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL9370388 | 0.90 | LMNA (0.66) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10890981 | 0.88 | NPC1 (0.43) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL11266576 | 0.88 | LMNA (0.45) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL11213713 | 0.86 | LMNA (0.47) | LMNATUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12496374-B2 | Deodorizer composition, absorbing body, and absorbent article | SUMITOMO SEIKA CHEMICALS CO, LTD. (JP) | 2025-12-16 | — | — | US | claimed |
| US-20250352518-A1 | A BENZIMIDAZOLE COMPOUND WITH ANTIHELMINTHIC ACTIVITY FOR USE IN REVERSING, ARRESTING OR SLOWING DOWN CELLULAR AGEING IN A VERTEBRATE SUBJECT | RAVAN BIO LIMITED (GB) | 2025-11-20 | — | — | US | claimed |
| EP-3923988-B1 | TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA | SOM INNOVATION BIOTECH S A (ES) | 2025-04-30 | — | — | EP | claimed |
| EP-4539808-A1 | A BENZIMIDAZOLE COMPOUND WITH ANTIHELMINTHIC ACTIVITY FOR USE IN REVERSING, ARRESTING OR SLOWING DOWN CELLULAR AGEING IN A VERTEBRATE SUBJECT | Ravan Bio Limited (GB) | 2025-04-23 | — | — | EP | claimed |
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20250100947-A1 | NITROUS OXIDE INHIBITOR | HIS MAJESTY THE KING IN RIGHT OF NEW ZEALAND ACTING THROUGH THE MINISTRY FOR PRIMARY INDUSTRIES (NZ) | 2025-03-27 | — | — | US | claimed |
| EP-4452907-A1 | NITROUS OXIDE INHIBITOR | His Majesty the King In Right of New Zealand Acting Through the Ministry for Primary Industries (NZ) | 2024-10-30 | — | — | EP | claimed |
| CN-118715194-A | Nitrous oxide inhibitors | 新西兰国王陛下通过初级产业部 | 2024-09-27 | — | — | CN | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| WO-2024172666-A1 | NITRIFICATION INHIBITOR | NEWTON PAUL CHARLES DUMMERE (NZ) | 2024-08-22 | — | — | WO | claimed |
| WO-1994027598-A1 | ANTIPARASITIC COMPOSITIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1994-12-08 | — | — | WO | claimed |
| CN-1095061-A | Use disulfonyl methylmethane control parasite | LILLY CO ELI (US) | 1994-11-16 | — | — | CN | claimed |
| US-5340804-A | In vertebrate animals | ELI LILLY AND COMPANY (US) | 1994-08-23 | — | — | US | claimed |
| EP-0606756-A1 | Use of disulfonyl methanes for the control of parasites | ELI LILLY AND COMPANY (US) | 1994-07-20 | — | — | EP | claimed |
| EP-0546687-A2 | Formazan parasiticides | ELI LILLY AND COMPANY (US) | 1993-06-16 | — | — | EP | claimed |
| EP-0505389-A4 | ANTIPARASITIC COMPOSITION FOR ANIMAL USE | — | 1992-12-02 | — | — | EP | claimed |
| EP-0505389-A1 | ANTIPARASITIC COMPOSITION FOR ANIMAL USE. | SMITHKLINE BEECHAM CORP (US) | 1992-09-30 | — | — | EP | claimed |
| CN-1053549-A | Antiparasitic composition for animals | SMITHKLINE BEECHAM CORP (US) | 1991-08-07 | — | — | CN | claimed |
| WO-1991008669-A1 | ANTIPARASITIC COMPOSITION FOR ANIMAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 1991-06-27 | — | — | WO | claimed |
| EP-0224257-A1 | Stabilized benzimidazole derivatives | SYNTEX (U.S.A.) INC. (US) | 1987-06-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352518-A1 | A BENZIMIDAZOLE COMPOUND WITH ANTIHELMINTHIC ACTIVITY FOR USE IN REVERSING, ARRESTING OR SLOWING DOWN CELLULAR AGEING IN A VERTEBRATE SUBJECT | ACHE, PDE5A, PDE3A | LMNA 1307/4885TUBB4A 1471/4885TUBB 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.